Indoco Remedies Limited (INDOCO) — Board Meeting Announcement

StockFin.ai Try Free →

📢 Key Event
Board approved ATB for ophthalmic division sale to Sunways (India) Private Limited.

🔄 What Changed
Approved sale of ophthalmic division for **₹110 crores**, representing 3.2% of standalone revenue.

🔮 What's Next
Transaction expected to close in about three months subject to conditions precedent.

💡 Investor Takeaway
The sale monetizes a non-core asset and may improve focus on higher-growth therapeutic areas.

Indoco Remedies announced the execution of an Agreement to Transfer Business (ATB) to sell its non-core ophthalmic division in India and select African markets as a going concern. The transaction, valued at **₹110 crores**, involves Sunways (India) Private Limited and is expected to close within three months pending regulatory approvals. The ophthalmic unit contributed **3.2%** of the company's standalone revenue of **₹47.79 crores** in FY2025, representing a small but strategic divestment to sharpen focus on core therapeutic areas.

📄 View Original Announcement (PDF)

📊 Stock Analysis — INDOCO ✨ Ask AI About This

About Indoco Remedies Limited (INDOCO)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹2,075.91 Cr P/E: -142.3

View full INDOCO stock details →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Indoco Remedies Limited (INDOCO) — Board Meeting Announcement

About Indoco Remedies Limited (INDOCO)

Recent Announcements from Indoco Remedies Limited